Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   AML, Adult;   CLL;   CLL, Relapsed;   CLL, Refractory Interventions:   Drug: Pitavastatin;   Drug: Venetoclax Sponsors:   University of California, Irvine;   United States Department of Defense Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

CONCLUSIONS: There was no convincing evidence of an increased risk in any hematological malignancy when interpreting the results from both series of analyses. PMID: 32818321 [PubMed - as supplied by publisher]
Source: Transfusion - Category: Hematology Authors: Tags: Transfusion Source Type: research
Conditions:   Acute Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   AML, Adult;   CLL;   CLL, Relapsed;   CLL, Refractory Interventions:   Drug: Pitavastatin;   Drug: Venetoclax Sponsors:   University of California, Irvine;   United States Department of Defense Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractThe major sources of the data on the hematological malignancies in the post-Chernobyl period in the regions of Ukraine differing by the levels of the residual contamination with radionuclides have been analyzed. According to the data collected from the primary hematological facilities in Ukraine in 2010 –2017, the incidence of lymphoid neoplasms from mature B cells, acute myeloid leukemia, and multiple myeloma in the most contaminated regions was higher than in the less contaminated ones. For the first time, the relative contribution of the several specific types of leukemia in the total diagnose d hematologi...
Source: Annals of Hematology - Category: Hematology Source Type: research
ConclusionsA significant decrease in leukemia incidence was observed between 1990 and 2017. However, in the same period, the incidence rates of AML and CLL significantly increased in most countries, suggesting that both types of leukemia might become a major global public health concern.
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research
Acute myeloid leukemia (AML) in the setting of Noonan syndrome (NS) has been reported before without clear guidelines for treatment or prognosis in these subgroups of patients, most likely due to its rarity and incomplete understanding of the pathogenesis of both diseases. In the current era of next-generation sequencing-based genomic analysis, we can better identify patients with NS with more accurate AML-related prognostic markers. Germline mutations inPTPN11 are the most common cause of NS. Somatic mutations inNPM1 occur frequently in AML. Here, we describe a young adult patient with a novel combined germlinePTPN11 and ...
Source: Acta Haematologica - Category: Hematology Source Type: research
Abstract Acute myeloid leukemia (AML) in the setting of Noonan syndrome (NS) has been reported before without clear guidelines for treatment or prognosis in these subgroups of patients, most likely due to its rarity and incomplete understanding of the pathogenesis of both diseases. In the current era of next-generation sequencing-based genomic analysis, we can better identify patients with NS with more accurate AML-related prognostic markers. Germline mutations in PTPN11 are the most common cause of NS. Somatic mutations in NPM1 occur frequently in AML. Here, we describe a young adult patient with a novel combined...
Source: Acta Haematologica - Category: Hematology Authors: Tags: Acta Haematol Source Type: research
Basel, 23 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine appeared consistent with the known safety profile ...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Research